Barcelona, Spain. From November 30, 2022Almirala global biopharmaceutical company focused on skin health, today announced Mercedes Diz will become Vice President of Corporate Strategy and will join Almiral’s Management Board effective December 1..
Diz joined Almirall in 2002 and will serve as Senior Director of Corporate Strategy from 2021. Almiral Key Strategic Processes and Projects and define priorities for achieving the company’s long-term goals in medical dermatology.
Among her previous roles in Almiral, Diz Responsible for managing commercial activities in several affiliates (Austria, Belgium, Netherlands, Nordics, Poland, Switzerland, UK), and major global commercial support functions such as Global Alliance Management & Partners, Licensing & Corporate Development. From 2018 to 2020, Diz successfully led the global marketing and market access team responsible for the company’s strategic global brands.In office, Almiral Launched first biologic to the psoriasis market.
Mercedes Diz holds a degree in Biochemistry and Molecular Biology from the Autonomous University of Madrid. Prior to Almirall, he held local sales and marketing roles at Pfizer, Allergan, DuPont Pharma and J&J.
“Mercedes has played an important role in the company and has led strategic projects for Almiral, in which, together with a multidisciplinary team, Mercedes has formulated a long-term strategic plan for Almiral, aiming to become the best medical dermatology company. We have set priorities for our journey to becomingCarlos Gallardo, Chairman and Interim CEO of Almirall, said:. “I am confident she will continue to bring great value to Almiral as a new member of the Board.” he adds.
“I am delighted to take on this new challenge and continue to contribute to the company’s growth. My appointment also reflects Almiral’s commitment to fostering talent development within the company. I want to thank the incredible colleagues and leaders who inspire me every day as we pursue our purpose of transforming the world for patients.”say Mercedes Diz, Almirall’s Vice President of Corporate Strategy, said:
Almirall is a global biopharmaceutical company focused on skin health. We work with scientists and medical professionals to address patient needs and improve their lives through science. Our noble purpose is at the heart of our work. “Changing the world of patients by helping them realize their hopes and dreams for a healthy life”. Bringing you innovative solutions.
Founded in 1943 and headquartered in Barcelona, the company is listed on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has focused on patient needs. Almirall has direct presence in 21 countries, strategic contracts in over 70 countries and approximately 1,800 employees. Total revenue in 2021 was €836.5 million.
For more information, see: amirall.com